Reversible cerebral vasoconstriction syndrome and posterior reversible encephalopathy syndrome following vaccination: analysis of the VAERS database and systematic review

被引:1
|
作者
Srichawla, Bahadar S. [1 ,3 ]
Fang, Ton [1 ]
Kipkorir, Vincent [2 ]
Garcia-Dominguez, Maria A. [1 ]
机构
[1] Univ Massachusetts, Chan Med Sch, Dept Neurol, Worcester, MA USA
[2] Univ Nairobi, Dept Med, Nairobi, Kenya
[3] 55 Lake Ave N, Worcester, MA 01655 USA
来源
ANNALS OF MEDICINE AND SURGERY | 2024年 / 86卷 / 03期
关键词
posterior reversible encephalopathy syndrome; PRES; RCVS; reversible cerebral vasoconstriction syndrome; vaccination; vaccine;
D O I
10.1097/MS9.0000000000001407
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives:This study aimed to analyze the Vaccine Adverse Event Reporting System (VAERS) database and systematically review the literature to provide a comprehensive analysis of reversible cerebral vasoconstriction syndrome (RCVS) and posterior reversible encephalopathy syndrome (PRES) secondary to vaccination.Methods:The authors analyzed the VAERS database and conducted a systematic review following PRISMA guidelines. The inclusion criteria for VAERS data were a score of >= 3 on the RCVS2 score and/or radiographic findings consistent with the diagnosis of RCVS or PRES. The systematic review was registered with PROSPERO.Results:Our combined data set included 29 cases (9 RCVS and 20 PRES). Most cases were women (72.4%) with a mean age of 50.7 years (SD 19.4 years). Most cases were associated with COVID-19 mRNA vaccines (58.6% Moderna, 20.7% Pfizer). Hypertension (37.9%), hyperlipidemia (13.7%), chronic kidney disease (CKD) (10.3%), and end-stage renal disease (6.8%) were common comorbidities. Furthermore, 20.6% (6/29) of cases were on immunosuppression therapy for various reasons. The mean time to symptom onset was 10.49 days after vaccination (SD 18.60), and the mean duration of hospitalization was 7.42 days (SD 5.94). The symptoms reported the most frequently were headache (41.3%), elevated blood pressure (31.0%), and emesis (17.2%). Typical radiographic findings included T2/FLAIR hyperintensities affecting the parieto-occipital lobes, indicative of vasogenic and/or cytotoxic edema.Conclusions:This study provides a comprehensive analysis of postvaccine RCVS and PRES. Both disease states were seen most often in those with pre-existing risk factors such as female sex, age over 50, hypertension, renal disease, and immunosuppression. Vaccines and their associated immune response may cause endothelial dysfunction leading to cerebral vasospasm and loss of cerebral autoregulation. However, further research is required to understand the underlying pathophysiological mechanisms. Despite the associations found, the absolute risk of these syndromes remains extremely low compared to the immense benefits of vaccination.
引用
收藏
页码:1251 / 1260
页数:10
相关论文
共 50 条
  • [31] A Pediatric Case of Reversible Cerebral Vasoconstriction Syndrome With Similar Radiographic Findings to Posterior Reversible Encephalopathy Syndrome
    Kamide, Tomoya
    Tsutsui, Taishi
    Misaki, Kouichi
    Sano, Hiroki
    Mohri, Masanao
    Uchiyama, Naoyuki
    Nakada, Mitsutoshi
    PEDIATRIC NEUROLOGY, 2017, 71 : 73 - 76
  • [32] Posterior Reversible Encephalopathy Syndrome and Reversible Cerebral Vasoconstriction Syndrome Distinct Clinical Entities with Overlapping Pathophysiology
    Levitt, Alex
    Zampolin, Richard
    Burns, Judah
    Bello, Jacqueline A.
    Slasky, Shira E.
    RADIOLOGIC CLINICS OF NORTH AMERICA, 2019, 57 (06) : 1133 - +
  • [33] Posterior Reversible Encephalopathy and Cerebral Vasoconstriction in a Patient With Hemolytic Uremic Syndrome
    Agarwal, Rajkumar
    Davis, Cresha
    Altinok, Deniz
    Serajee, Fatema J.
    PEDIATRIC NEUROLOGY, 2014, 50 (05) : 518 - 521
  • [34] Clinical relevance of reversible cerebral vasoconstriction syndrome in pregnant women with posterior reversible encephalopathy syndrome: review of case reports in Japan
    Hirotada Suzuki
    Akihide Ohkuchi
    Kenji Horie
    Manabu Ogoyama
    Rie Usui
    Hironori Takahashi
    Hiroyuki Fujiwara
    Hypertension Research, 2024, 47 : 1288 - 1297
  • [35] Clinical relevance of reversible cerebral vasoconstriction syndrome in pregnant women with posterior reversible encephalopathy syndrome: review of case reports in Japan
    Suzuki, Hirotada
    Ohkuchi, Akihide
    Horie, Kenji
    Ogoyama, Manabu
    Usui, Rie
    Takahashi, Hironori
    Fujiwara, Hiroyuki
    HYPERTENSION RESEARCH, 2024, 47 (05) : 1288 - 1297
  • [37] Reversible Cerebral Vasoconstriction Syndrome along with Posterior Reversible Encephalopathy Syndrome in a Postnatal Eclamptic Patient: A Case Report
    Patel, Nainita
    Chaudhari, Kamlesh
    Dave, Apoorva
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2023, 17 (09) : QD5 - QD7
  • [38] Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome associated spinal subdural hematoma A case report
    Chen, Hanfeng
    Xu, Ziqi
    Yuan, Yuan
    MEDICINE, 2020, 99 (31) : E21522
  • [40] Reversible cerebral vasoconstriction syndrome: a comprehensive systematic review
    Song, T. J.
    Lee, K. H.
    Li, H.
    Kim, J. Y.
    Chang, K.
    Kim, S. H.
    Han, K. H.
    Kim, B. Y.
    Kronbichler, A.
    Ducros, A.
    Koyanagi, A.
    Jacob, L.
    KiM, M. S.
    Yon, D. K.
    Lee, S. W.
    Yang, J. M.
    Hong, S. H.
    Ghayda, R. A.
    Kang, J. W.
    Shin, J., I
    Smith, L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (09) : 3519 - 3529